Overcoming Barriers to Drug Development in Children with CKD.

Area of Science:

• Pediatric Nephrology
• Pharmacology
• Regulatory Science

Background:

• Children with chronic kidney disease (CKD) require age-appropriate medications.
• Pediatric drug development faces significant hurdles, including recruitment and completion challenges in clinical trials.
• There's a notable delay in obtaining pediatric-specific labeling for drugs approved for adults.

Purpose of the Study:

• To examine challenges in drug development for pediatric chronic kidney disease (CKD).
• To review regulatory frameworks in the US and EU governing pediatric drug development.
• To identify progress and propose solutions for facilitating pediatric CKD drug trials.

Main Methods:

• Convened a diverse stakeholder workgroup, including representatives from the Food and Drug Administration (FDA) and European Medicines Agency (EMA).
• Analyzed existing regulatory landscapes in the United States and European Union.
• Reviewed the current status of drug development and approval for children with CKD.

Main Results:

• Drug development for pediatric CKD faces unique challenges in trial conduct and execution.
• Legislation exists to incentivize or mandate pediatric drug programs, yet progress is slow.
• Substantial time lags persist between adult and pediatric drug approval for the same indications.

Conclusions:

• Overcoming challenges in pediatric CKD drug development requires a multi-stakeholder approach.
• Streamlining regulatory processes and improving trial methodologies are crucial.
• Facilitating drug development for children with CKD is essential for their health and treatment outcomes.